Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + trastuzumab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
A **three-drug combination therapy** of buparlisib (an oral pan-class I PI3K inhibitor), trastuzumab (a monoclonal antibody against human epidermal growth factor receptor 2 or HER2), and paclitaxel (a taxane-class microtubule inhibitor chemotherapy), primarily investigated as a neoadjuvant or advanced/metastatic treatment for breast cancer, particularly HER2-positive subtypes. The regimen aims to inhibit cancer cell growth and survival via blockade of PI3K pathway signaling (buparlisib), HER2 receptor targeting (trastuzumab), and microtubule stabilization leading to mitotic arrest (paclitaxel). Early phase studies show feasibility of administration, but efficacy over standard combinations is not established in phase II/III trials[1][4][7].
- Other names
- BKM120 + paclitaxel + trastuzumabbuparlisib + paclitaxel + trastuzumab
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on buparlisib + trastuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + trastuzumab + paclitaxel.